Symbols / KYMR
KYMR Chart
About
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.82B |
| Enterprise Value | 6.05B | Income | -311.35M | Sales | 39.21M |
| Book/sh | 19.42 | Cash/sh | 10.39 | Dividend Yield | — |
| Payout | 0.00% | Employees | 238 | IPO | — |
| P/E | — | Forward P/E | -20.78 | PEG | — |
| P/S | 173.84 | P/B | 4.30 | P/C | — |
| EV/EBITDA | -17.86 | EV/Sales | 154.30 | Quick Ratio | 10.19 |
| Current Ratio | 10.47 | Debt/Eq | 5.21 | LT Debt/Eq | — |
| EPS (ttm) | -3.69 | EPS next Y | -4.02 | EPS Growth | — |
| Revenue Growth | -61.20% | Earnings | 2026-05-08 | ROA | -15.88% |
| ROE | -25.78% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -34.11% | Profit Margin | 0.00% | Shs Outstand | 81.64M |
| Shs Float | 54.42M | Short Float | 14.76% | Short Ratio | 13.07 |
| Short Interest | — | 52W High | 103.00 | 52W Low | 19.45 |
| Beta | 2.30 | Avg Volume | 903.72K | Volume | 557.25K |
| Target Price | $119.71 | Recom | Strong_buy | Prev Close | $83.52 |
| Price | $83.49 | Change | -0.04% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$119.71
Mean price target
2. Current target
$83.49
Latest analyst target
3. DCF / Fair value
$-29.99
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$83.49
Low
$91.00
High
$140.00
Mean
$119.71
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-03 | main | UBS | Buy → Buy | $128 |
| 2026-03-02 | main | Citigroup | Buy → Buy | $120 |
| 2026-03-02 | main | Stephens & Co. | Overweight → Overweight | $100 |
| 2026-02-26 | main | BTIG | Buy → Buy | $134 |
| 2026-02-26 | main | Piper Sandler | Overweight → Overweight | $140 |
| 2026-02-03 | reit | BTIG | Buy → Buy | $138 |
| 2026-01-28 | main | Barclays | Overweight → Overweight | $133 |
| 2026-01-15 | reit | BTIG | Buy → Buy | $138 |
| 2026-01-06 | down | Wolfe Research | Outperform → Peer Perform | — |
| 2025-12-22 | main | B. Riley Securities | Buy → Buy | $117 |
| 2025-12-16 | main | RBC Capital | Outperform → Outperform | $103 |
| 2025-12-11 | main | Stephens & Co. | Overweight → Overweight | $110 |
| 2025-12-11 | main | Mizuho | Outperform → Outperform | $120 |
| 2025-12-10 | main | JP Morgan | Overweight → Overweight | $125 |
| 2025-12-09 | main | Jefferies | Buy → Buy | $122 |
| 2025-12-09 | main | Citigroup | Buy → Buy | $110 |
| 2025-12-09 | main | Wells Fargo | Overweight → Overweight | $116 |
| 2025-12-09 | main | Truist Securities | Buy → Buy | $116 |
| 2025-12-09 | main | Oppenheimer | Outperform → Outperform | $120 |
| 2025-12-09 | main | Morgan Stanley | Overweight → Overweight | $127 |
- How (KYMR) Movements Inform Risk Allocation Models - Stock Traders Daily Mon, 09 Mar 2026 00
- Bruce Jacobs Sells 7,576 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat hu, 05 Mar 2026 01
- Kymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical Phase (NASDAQ:KYMR) - Seeking Alpha ue, 03 Mar 2026 12
- UBS Raises Price Target for Kymera Therapeutics (KYMR) to $128 | - GuruFocus ue, 03 Mar 2026 19
- Oral eczema and asthma drug in Phase 2b, Kymera sitting on $1.6B cash - Stock Titan hu, 26 Feb 2026 12
- KYMERA THERAPEUTICS ($KYMR) Releases Q4 2025 Earnings - Quiver Quantitative hu, 26 Feb 2026 12
- How Kymera’s Bigger Losses and New Equity Plans May Impact Kymera Therapeutics (KYMR) Investors - simplywall.st ue, 03 Mar 2026 14
- Assessing Kymera Therapeutics (KYMR) Valuation After Its Strong Recent Share Price Momentum - Yahoo Finance ue, 24 Feb 2026 08
- Kymera Therapeutics, Inc. $KYMR Shares Acquired by Rafferty Asset Management LLC - MarketBeat Wed, 04 Mar 2026 11
- Degrader-medicine biotech Kymera lines up March investor talks - Stock Titan ue, 24 Feb 2026 08
- Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance hu, 26 Feb 2026 08
- Kymera Therapeutics (KYMR): Citigroup Raises Price Target, Reaff - GuruFocus Mon, 02 Mar 2026 19
- Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 81,866 Shares of Stock - MarketBeat Wed, 04 Mar 2026 23
- Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells 2,039 Shares of Stock - MarketBeat hu, 05 Mar 2026 01
- Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CFO Sells 4,895 Shares of Stock - MarketBeat hu, 05 Mar 2026 01
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5958 | 515594 | — | Sale at price 84.00 - 89.66 per share. | CHADWICK JEREMY G | Chief Operating Officer | — | 2026-03-04 00:00:00 | D |
| 1 | 10508 | 916669 | — | Sale at price 84.00 - 89.66 per share. | GOLLOB JARED AUGUST | Officer | — | 2026-03-04 00:00:00 | D |
| 2 | 12471 | 1091231 | — | Sale at price 84.00 - 89.66 per share. | JACOBS BRUCE N. | Chief Financial Officer | — | 2026-03-04 00:00:00 | D |
| 3 | 12575 | — | — | Stock Award(Grant) at price 0.00 per share. | CHADWICK JEREMY G | Chief Operating Officer | — | 2026-03-02 00:00:00 | D |
| 4 | 17650 | — | — | Stock Award(Grant) at price 0.00 per share. | GOLLOB JARED AUGUST | Officer | — | 2026-03-02 00:00:00 | D |
| 5 | 17650 | — | — | Stock Award(Grant) at price 0.00 per share. | JACOBS BRUCE N. | Chief Financial Officer | — | 2026-03-02 00:00:00 | D |
| 6 | 9225 | — | — | Stock Award(Grant) at price 0.00 per share. | GOODMAN NOAH | Officer | — | 2026-03-02 00:00:00 | D |
| 7 | 30000 | 2707813 | — | Sale at price 89.78 - 93.49 per share. | MAINOLFI NELLO | Chief Executive Officer | — | 2026-02-25 00:00:00 | D |
| 8 | 30000 | 62400 | — | Conversion of Exercise of derivative security at price 2.08 per share. | MAINOLFI NELLO | Chief Executive Officer | — | 2026-02-25 00:00:00 | D |
| 9 | 2500 | 218270 | — | Sale at price 87.06 - 88.10 per share. | ESPOSITO PAMELA | Director | — | 2026-02-20 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -298.81M | -211.31M | -143.20M | -151.66M |
| TotalUnusualItems | -3.85M | -4.92M | 0.00 | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -3.85M | -4.92M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -311.35M | -223.86M | -146.96M | -154.81M |
| ReconciledDepreciation | 8.31M | 7.37M | 3.56M | 2.98M |
| EBITDA | -302.67M | -216.24M | -143.20M | -151.66M |
| EBIT | -310.98M | -223.61M | -146.77M | -154.63M |
| NetInterestIncome | 38.05M | 37.78M | 18.57M | 6.45M |
| InterestExpense | 370.00K | 249.00K | 196.00K | 176.00K |
| InterestIncome | 38.42M | 38.03M | 18.76M | 6.62M |
| NormalizedIncome | -307.50M | -218.93M | -146.96M | -154.81M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -311.35M | -223.86M | -146.96M | -154.81M |
| TotalExpenses | 384.75M | 303.78M | 244.12M | 208.08M |
| TotalOperatingIncomeAsReported | -349.40M | -261.63M | -165.53M | -161.26M |
| DilutedAverageShares | 75.04M | 58.37M | 53.93M | 47.99M |
| BasicAverageShares | 75.04M | 58.37M | 53.93M | 47.99M |
| DilutedEPS | -2.98 | -2.52 | -2.87 | -2.09 |
| BasicEPS | -2.98 | -2.52 | -2.87 | -2.09 |
| DilutedNIAvailtoComStockholders | -311.35M | -223.86M | -146.96M | -154.81M |
| NetIncomeCommonStockholders | -311.35M | -223.86M | -146.96M | -154.81M |
| NetIncome | -311.35M | -223.86M | -146.96M | -154.81M |
| NetIncomeIncludingNoncontrollingInterests | -311.35M | -223.86M | -146.96M | -154.81M |
| NetIncomeContinuousOperations | -311.35M | -223.86M | -146.96M | -154.81M |
| PretaxIncome | -311.35M | -223.86M | -146.96M | -154.81M |
| OtherIncomeExpense | -3.85M | -4.92M | ||
| SpecialIncomeCharges | -3.85M | -4.92M | 0.00 | 0.00 |
| ImpairmentOfCapitalAssets | 3.85M | 4.92M | 0.00 | 0.00 |
| NetNonOperatingInterestIncomeExpense | 38.05M | 37.78M | 18.57M | 6.45M |
| InterestExpenseNonOperating | 370.00K | 249.00K | 196.00K | 176.00K |
| InterestIncomeNonOperating | 38.42M | 38.03M | 18.76M | 6.62M |
| OperatingIncome | -345.54M | -256.71M | -165.53M | -161.26M |
| OperatingExpense | 384.75M | 303.78M | 244.12M | 208.08M |
| ResearchAndDevelopment | 316.57M | 240.25M | 189.08M | 164.25M |
| SellingGeneralAndAdministration | 68.19M | 63.53M | 55.04M | 43.83M |
| GeneralAndAdministrativeExpense | 68.19M | 63.53M | 55.04M | 43.83M |
| OtherGandA | 68.19M | 63.53M | 55.04M | 43.83M |
| TotalRevenue | 39.21M | 47.07M | 78.59M | 46.83M |
| OperatingRevenue | 39.21M | 47.07M | 78.59M | 46.83M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 81.32M | 64.89M | 55.59M | 55.04M |
| ShareIssued | 81.32M | 64.89M | 55.59M | 55.04M |
| TotalDebt | 82.25M | 87.76M | 84.67M | 17.34M |
| TangibleBookValue | 1.58B | 835.62M | 394.97M | 490.15M |
| InvestedCapital | 1.58B | 835.62M | 394.97M | 490.15M |
| WorkingCapital | 788.00M | 442.50M | 319.63M | 348.07M |
| NetTangibleAssets | 1.58B | 835.62M | 394.97M | 490.15M |
| CapitalLeaseObligations | 82.25M | 87.76M | 84.67M | 17.34M |
| CommonStockEquity | 1.58B | 835.62M | 394.97M | 490.15M |
| TotalCapitalization | 1.58B | 835.62M | 394.97M | 490.15M |
| TotalEquityGrossMinorityInterest | 1.58B | 835.62M | 394.97M | 490.15M |
| StockholdersEquity | 1.58B | 835.62M | 394.97M | 490.15M |
| GainsLossesNotAffectingRetainedEarnings | 1.80M | -1.49M | -552.00K | -4.95M |
| OtherEquityAdjustments | 1.80M | -1.49M | -552.00K | -4.95M |
| RetainedEarnings | -1.07B | -754.61M | -530.75M | -383.79M |
| AdditionalPaidInCapital | 2.64B | 1.59B | 926.27M | 878.88M |
| CapitalStock | 8.00K | 7.00K | 6.00K | 6.00K |
| CommonStock | 8.00K | 7.00K | 6.00K | 6.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 163.15M | 142.42M | 180.79M | 112.98M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 79.94M | 74.65M | 95.10M | 41.64M |
| OtherNonCurrentLiabilities | 248.00K | 66.00K | ||
| NonCurrentDeferredLiabilities | 11.44M | 0.00 | 16.77M | 28.00M |
| NonCurrentDeferredRevenue | 11.44M | 0.00 | 16.77M | 28.00M |
| LongTermDebtAndCapitalLeaseObligation | 68.50M | 74.65M | 78.33M | 13.39M |
| LongTermCapitalLeaseObligation | 68.50M | 74.65M | 78.33M | 13.39M |
| CurrentLiabilities | 83.21M | 67.77M | 85.69M | 71.34M |
| OtherCurrentLiabilities | 242.00K | 223.00K | 524.00K | 303.00K |
| CurrentDeferredLiabilities | 22.93M | 13.58M | 37.88M | 35.26M |
| CurrentDeferredRevenue | 22.93M | 13.58M | 37.88M | 35.26M |
| CurrentDebtAndCapitalLeaseObligation | 13.76M | 13.11M | 6.34M | 3.94M |
| CurrentCapitalLeaseObligation | 13.76M | 13.11M | 6.34M | 3.94M |
| PayablesAndAccruedExpenses | 46.29M | 40.86M | 40.94M | 31.84M |
| CurrentAccruedExpenses | 42.27M | 34.87M | 33.86M | 27.50M |
| Payables | 4.01M | 5.99M | 7.08M | 4.33M |
| AccountsPayable | 4.01M | 5.99M | 7.08M | 4.33M |
| TotalAssets | 1.74B | 978.03M | 575.76M | 603.13M |
| TotalNonCurrentAssets | 871.60M | 467.77M | 170.44M | 183.72M |
| OtherNonCurrentAssets | 14.91M | 7.74M | 7.93M | 9.15M |
| InvestmentsAndAdvances | 771.16M | 362.16M | 61.43M | 152.33M |
| InvestmentinFinancialAssets | 771.16M | 362.16M | 61.43M | 152.33M |
| AvailableForSaleSecurities | 771.16M | 362.16M | 61.43M | 152.33M |
| NetPPE | 85.53M | 97.86M | 101.08M | 22.24M |
| AccumulatedDepreciation | -22.13M | -16.07M | -10.44M | -6.89M |
| GrossPPE | 107.65M | 113.94M | 111.52M | 29.14M |
| Leases | 42.99M | 44.01M | 7.80M | 7.80M |
| ConstructionInProgress | 1.15M | 66.00K | ||
| OtherProperties | 53.74M | 57.93M | 42.40M | 5.53M |
| MachineryFurnitureEquipment | 10.92M | 11.99M | 8.37M | 6.90M |
| BuildingsAndImprovements | 47.41M | 52.95M | 8.91M | 9.43M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 871.21M | 510.27M | 405.32M | 419.42M |
| OtherCurrentAssets | 22.94M | 21.52M | 11.67M | 9.71M |
| PrepaidAssets | 8.72M | |||
| Receivables | 947.00K | 18.76M | 2.54M | 135.00K |
| OtherReceivables | 947.00K | 3.76M | 2.54M | 135.00K |
| AccountsReceivable | 0.00 | 15.00M | 0.00 | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 848.28M | 488.74M | 374.88M | 407.17M |
| OtherShortTermInvestments | 491.26M | 368.49M | 264.92M | 338.77M |
| CashAndCashEquivalents | 357.01M | 120.26M | 109.97M | 68.39M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -234.34M | -207.34M | -137.31M | -155.92M |
| RepaymentOfDebt | -1.49M | -1.58M | -76.00K | -1.13M |
| IssuanceOfCapitalStock | 928.90M | 596.62M | 0.00 | 149.82M |
| CapitalExpenditure | -1.45M | -12.84M | -34.48M | -2.84M |
| InterestPaidSupplementalData | 312.00K | 206.00K | 162.00K | 179.00K |
| EndCashPosition | 362.81M | 126.05M | 115.78M | 74.53M |
| BeginningCashPosition | 126.05M | 115.78M | 74.53M | 54.09M |
| ChangesInCash | 236.76M | 10.27M | 41.25M | 20.43M |
| FinancingCashFlow | 990.71M | 608.85M | 4.19M | 153.00M |
| CashFlowFromContinuingFinancingActivities | 990.71M | 608.85M | 4.19M | 153.00M |
| NetOtherFinancingCharges | -397.00K | |||
| ProceedsFromStockOptionExercised | 63.31M | 13.81M | 4.27M | 4.30M |
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 928.90M | 596.62M | 0.00 | 149.82M |
| CommonStockIssuance | 928.90M | 596.62M | 0.00 | 149.82M |
| NetIssuancePaymentsOfDebt | -1.49M | -1.58M | -76.00K | -1.13M |
| NetLongTermDebtIssuance | -1.49M | -1.58M | -76.00K | -1.13M |
| LongTermDebtPayments | -1.49M | -1.58M | -76.00K | -1.13M |
| InvestingCashFlow | -521.06M | -404.08M | 139.89M | 20.52M |
| CashFlowFromContinuingInvestingActivities | -521.06M | -404.08M | 139.89M | 20.52M |
| NetInvestmentPurchaseAndSale | -519.61M | -391.24M | 174.37M | 23.36M |
| SaleOfInvestment | 488.02M | 509.99M | 363.52M | 469.33M |
| PurchaseOfInvestment | -1.01B | -901.23M | -189.15M | -445.97M |
| NetPPEPurchaseAndSale | -1.45M | -12.84M | -34.48M | -2.84M |
| PurchaseOfPPE | -1.45M | -12.84M | -34.48M | -2.84M |
| OperatingCashFlow | -232.89M | -194.50M | -102.83M | -153.09M |
| CashFlowFromContinuingOperatingActivities | -232.89M | -194.50M | -102.83M | -153.09M |
| ChangeInWorkingCapital | 15.27M | -23.97M | 2.68M | -37.62M |
| ChangeInOtherWorkingCapital | 13.64M | -41.22M | -7.73M | -38.52M |
| ChangeInOtherCurrentLiabilities | -5.04M | 1.92M | 18.58M | -1.00M |
| ChangeInOtherCurrentAssets | 2.67M | 2.54M | 4.80M | 517.00K |
| ChangeInPayablesAndAccruedExpense | 5.41M | 3.87M | 5.22M | 4.77M |
| ChangeInAccruedExpense | 7.39M | 4.18M | 3.18M | 4.52M |
| ChangeInPayable | -1.97M | -307.00K | 2.04M | 253.00K |
| ChangeInAccountPayable | -1.97M | -307.00K | 2.04M | 253.00K |
| ChangeInPrepaidAssets | -2.36M | -8.90M | -1.96M | -992.00K |
| ChangeInReceivables | 947.00K | 17.82M | -16.23M | -2.40M |
| ChangesInAccountReceivables | 0.00 | 15.00M | -15.00M | 0.00 |
| StockBasedCompensation | 59.90M | 55.01M | 43.12M | 35.48M |
| AssetImpairmentCharge | 3.86M | 4.92M | 0.00 | 0.00 |
| AmortizationOfSecurities | -8.88M | -13.98M | -5.23M | 889.00K |
| DepreciationAmortizationDepletion | 8.31M | 7.37M | 3.56M | 2.98M |
| DepreciationAndAmortization | 8.31M | 7.37M | 3.56M | 2.98M |
| OperatingGainsLosses | -5.23M | 889.00K | 5.83M | |
| GainLossOnInvestmentSecurities | -5.23M | 889.00K | 5.81M | |
| GainLossOnSaleOfPPE | 0.00 | 0.00 | 18.00K | |
| NetIncomeFromContinuingOperations | -311.35M | -223.86M | -146.96M | -154.81M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for KYMR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|